HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.

AbstractOBJECTIVES:
To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations.
METHODS:
A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six instillations of gemcitabine were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hours, was given at the dose of 500 mg, 1000 mg, and 2000 mg in groups of 9 patients each. A complete response (CR) was defined as negative cytology, cystoscopy, and biopsy findings. Patients achieving a CR received monthly maintenance for up to 1 year and underwent cytology and cystoscopy at 3-month intervals.
RESULTS:
Of the 27 patients, 1 was lost to follow-up, and of the remaining 26 patients, 6 (23%) achieved a CR. A CR was achieved in 1 patient (12.5%), 2 patients (22.2%), and 3 patients (33.3%) at a dose of 500, 1000, and 2000 mg, respectively. A partial response was obtained in 2 additional patients (22%) at a dose of 500 and 1000 mg. Bladder Tis was diagnosed in 2 patients with a CR at 3 and 8 months after treatment. The remaining 4 patients were disease free at a follow-up of up to 22 months. Systemic and local tolerability was excellent, and no treatment interruption was required.
CONCLUSIONS:
Our experience has shown the good tolerability and potential efficacy of intravesical gemcitabine against recurrent transitional cell carcinoma of the bladder. Gemcitabine might be proposed, if our results are confirmed by larger studies, as a second-line therapy in patients who cannot tolerate more aggressive intravesical therapy.
AuthorsVincenzo Serretta, Antonino Galuffo, Carlo Pavone, Rosalinda Allegro, Michele Pavone-MacAluso
JournalUrology (Urology) Vol. 65 Issue 1 Pg. 65-9 (Jan 2005) ISSN: 1527-9995 [Electronic] United States
PMID15667865 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Prodrugs
  • Deoxycytidine
  • Gemcitabine
Topics
  • Administration, Intravesical
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage, therapeutic use)
  • Carcinoma, Transitional Cell (drug therapy, pathology)
  • Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy)
  • Prodrugs (administration & dosage, therapeutic use)
  • Remission Induction
  • Salvage Therapy
  • Treatment Outcome
  • Urinary Bladder Neoplasms (drug therapy, pathology)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: